Érica Vieira Serrano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Érica Vieira Serrano has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Valéria Valim
Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil
11 shared publications - Samira Tatiyama Miyamoto
Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil
9 shared publications - Raquel Altoé Giovelli
Faculdade de Ciências da Educação e Saúde, Centro Universitário de Brasília, Brasília, Brazil
5 shared publications Luíza Vallory Alochio
Universidade Federal do Espírito Santo, Vitória (ES), Brazil
4 shared publicationsWeider Andrade Tomé
Universidade Federal do Espírito Santo, Vitória (ES), Brazil
4 shared publicationsAna Paula Truhlar Pedrini
Universidade Federal do Espírito Santo, Vitória (ES), Brazil
3 shared publications
Latest Publications
- Open Access
Primary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study
Introduction: The COVID-19 pandemic posed additional challenges for this vulnerable population, such as Sjögren’s disease (SjD), underscoring the need for effective and safe vaccination strategies. Objective: To evaluate the immunogenicity and safety of COVID-19 vaccines in patients with SjD. Methods: This prospective, observational, longitudinal study included SjD patients from the SAFER cohort. Immunogenicity was assessed via anti-spike IgG (IgG-S) titers using chemiluminescence reported as geometric mean titers (GMT) and fold increase in GMT (FI-GMT). Disease activity was evaluated using the ESSDAI score. Adverse events and COVID-19 infections were also monitored. Assessments were conducted at four time points: pre-first dose (T1), pre-second dose (T2), pre-booster (T3), and four weeks post-booster (T4). Primary vaccination involved ChAdOx1 nCoV-19 or inactivated vaccine (CoronaVac), and boosters were either homologous (ChAdOx1 nCoV-19) or heterologous (BNT162b2). Results: Among 51 participants (mean age 46 years; 90% female), 41% had comorbidities and 27% (n = 14/51) were highly immunosuppressed. Among those 73% (n = 37/51) under low immunosuppression, n = 8/51 (13%) were not using any medication. At baseline, 11% (n = 4/35) showed moderate/high disease activity, which decreased to 6.5% (n = 2/31) at T4. Primary vaccination was ChAdOx1 in 94% (n = 48/51) and CoronaVac in 6% (n = 3/51); 73% (n = 37/51) received heterologous and 27% (n = 14/51) homologous boosters. COVID-19 infection post-booster occurred in 20% (n = 10/51). Seroconversion rates reached nearly 100% across all medication subgroups except for biologic users, who showed delayed but stable seroconversion by T4. IgG-S titers increased progressively through T4. Primary immunization induced an ascending GMT in both vaccine types. At T4, the GMT was significantly higher in the BNT162b2 group (2148.03 [1452.05–3155.84]; p < 0.001; 95% CI) than in the ChAdOx1 group (324.29 [107.92–974.48]; p < 0.001; 95% CI); the fold-increase in immune response was six times greater with BNT162b2 (5.98 [2.97–12.03]; p = 0.001; 95% CI). Seroconversion was 100% in the heterologous group versus 83% in the homologous group (p > 0.01). Those with prior infection showed significantly higher titers, particularly at T2 and T3 (p < 0.001 for T1–T3). Adverse events were mild and not statistically significant. Multivariate regression confirmed BNT162b2 as an independent factor for higher antibody titers. Conclusion: COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity.
Open AccessPrimary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study
Introduction: The COVID-19 pandemic posed additional challenges for this vulnerable population, such as Sjögren’s disease (SjD), underscoring the need for effective and safe vaccination strategies. Objective: To evaluate the immunogenicity and safety of COVID-19 vaccines in patients with SjD. Methods: This prospective, observational, longitudinal study included SjD patients from the SAFER cohort. Immunogenicity was assessed via anti-spike IgG (IgG-S) titers using chemiluminescence reported as geometric mean titers (GMT) and fold increase in GMT (FI-GMT). Disease activity was evaluated using the ESSDAI score. Adverse events and COVID-19 infections were also monitored. Assessments were conducted at four time points: pre-first dose (T1), pre-second dose (T2), pre-booster (T3), and four weeks post-booster (T4). Primary vaccination involved ChAdOx1 nCoV-19 or inactivated vaccine (CoronaVac), and boosters were either homologous (ChAdOx1 nCoV-19) or heterologous (BNT162b2). Results: Among 51 participants (mean age 46 years; 90% female), 41% had comorbidities and 27% (n = 14/51) were highly immunosuppressed. Among those 73% (n = 37/51) under low immunosuppression, n = 8/51 (13%) were not using any medication. At baseline, 11% (n = 4/35) showed moderate/high disease activity, which decreased to 6.5% (n = 2/31) at T4. Primary vaccination was ChAdOx1 in 94% (n = 48/51) and CoronaVac in 6% (n = 3/51); 73% (n = 37/51) received heterologous and 27% (n = 14/51) homologous boosters. COVID-19 infection post-booster occurred in 20% (n = 10/51). Seroconversion rates reached nearly 100% across all medication subgroups except for biologic users, who showed delayed but stable seroconversion by T4. IgG-S titers increased progressively through T4. Primary immunization induced an ascending GMT in both vaccine types. At T4, the GMT was significantly higher in the BNT162b2 group (2148.03 [1452.05–3155.84]; p < 0.001; 95% CI) than in the ChAdOx1 group (324.29 [107.92–974.48]; p < 0.001; 95% CI); the fold-increase in immune response was six times greater with BNT162b2 (5.98 [2.97–12.03]; p = 0.001; 95% CI). Seroconversion was 100% in the heterologous group versus 83% in the homologous group (p > 0.01). Those with prior infection showed significantly higher titers, particularly at T2 and T3 (p < 0.001 for T1–T3). Adverse events were mild and not statistically significant. Multivariate regression confirmed BNT162b2 as an independent factor for higher antibody titers. Conclusion: COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity.
- Open Access
- 11 February 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1) , 1-16
Recommendations on neurologic, cognitive, and psychiatric manifestations in patients with Sjögren’s disease by the Brazilian Society of Rheumatology
Background: Neurological and psychiatric manifestations occur in patients with primary Sjogren’s disease (SjD) with a wide-ranging clinical presentation, affecting quality of life, social participation, and prognosis. Despite this, neither central nor peripheral neurological symptoms are systematically evaluated in the context of autoimmunity or identified as manifestations of SjD. The EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) covers only part of them in the neurological domain. Methods: We performed a systematic review of the diagnosis and prevalence of central, peripheral, and autonomic nervous system manifestations in primary SjD, following the recommendations proposed by the Cochrane Collaboration Handbook. Observational studies were included when their main issue was the diagnosis and the prevalence of the manifestations individually. We employed a generalized linear mixed model (GLMM) method with a random-effects model, and the results were computed using logit transformation, implemented through the ‘meta’ and ‘metafor’ packages in the R software (version 3.6.1). To present these recommendations, agreement among experts was investigated using the Delphi method in in-person meetings. Results: We propose ten recommendations regarding the investigation and management of neurological involvement in SjD that had 100% agreement among participants. Conclusion: These recommendations add to the literature on the clinical care of patients with SjD.
- 11 February 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 65 (1) , 1-16
Open AccessRecommendations on neurologic, cognitive, and psychiatric manifestations in patients with Sjögren’s disease by the Brazilian Society of Rheumatology
Background: Neurological and psychiatric manifestations occur in patients with primary Sjogren’s disease (SjD) with a wide-ranging clinical presentation, affecting quality of life, social participation, and prognosis. Despite this, neither central nor peripheral neurological symptoms are systematically evaluated in the context of autoimmunity or identified as manifestations of SjD. The EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) covers only part of them in the neurological domain. Methods: We performed a systematic review of the diagnosis and prevalence of central, peripheral, and autonomic nervous system manifestations in primary SjD, following the recommendations proposed by the Cochrane Collaboration Handbook. Observational studies were included when their main issue was the diagnosis and the prevalence of the manifestations individually. We employed a generalized linear mixed model (GLMM) method with a random-effects model, and the results were computed using logit transformation, implemented through the ‘meta’ and ‘metafor’ packages in the R software (version 3.6.1). To present these recommendations, agreement among experts was investigated using the Delphi method in in-person meetings. Results: We propose ten recommendations regarding the investigation and management of neurological involvement in SjD that had 100% agreement among participants. Conclusion: These recommendations add to the literature on the clinical care of patients with SjD.
- Open Access
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
SCLERODERMA OF BUSCHKE
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
Open AccessSCLERODERMA OF BUSCHKE
- Open Access
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
VALIDITY AND RELIABILITY OF THE BRAZILIAN VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUESTIONNAIRE
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
Open AccessVALIDITY AND RELIABILITY OF THE BRAZILIAN VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUESTIONNAIRE
- Open Access
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
LEUKOCYTOCLASTIC VASCULITIS AND THROMBOSIS IN PRIMARY SJÖGREN SYNDROME AFTER COVID-19: A CASE REPORT
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
Open AccessLEUKOCYTOCLASTIC VASCULITIS AND THROMBOSIS IN PRIMARY SJÖGREN SYNDROME AFTER COVID-19: A CASE REPORT
- Open Access
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
BRAZILIAN VERSION OF THE "PRIMARY SJÖGREN SYNDROME - QUALITY OF LIFE QUESTIONNAIRE (PSS-QOL)
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
Open AccessBRAZILIAN VERSION OF THE "PRIMARY SJÖGREN SYNDROME - QUALITY OF LIFE QUESTIONNAIRE (PSS-QOL)
- Open Access
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
PRIMARY SJÖGREN'S SYNDROME PATIENTS WITH BETTER LEVELS OF PHYSICAL ACTIVITY PRESENT LESS FATIGUE AND BETTER QUALITY OF LIFE
- 1 January 2021
- Published by Sociedade Brasileira de Reumatologia
Open AccessPRIMARY SJÖGREN'S SYNDROME PATIENTS WITH BETTER LEVELS OF PHYSICAL ACTIVITY PRESENT LESS FATIGUE AND BETTER QUALITY OF LIFE
- 2 January 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 227-238
Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren’s syndrome: a randomized-controlled trial
The aim of this study was to evaluate the safety and effectiveness of a supervised walking program in women with primary Sjögren’s syndrome (pSS).
- 2 January 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 227-238
Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren’s syndrome: a randomized-controlled trial
The aim of this study was to evaluate the safety and effectiveness of a supervised walking program in women with primary Sjögren’s syndrome (pSS).